Clemens Hufnagl

Salzburg, Austria

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

The Artisse Intrasaccular Device: A New Intrasaccular Flow Diverter for the Treatment of Cerebral Aneurysms.

The Artisse Intrasaccular Device: A New Intrasaccular Flow Diverter for the Treatment of Cerebral Aneurysms.

Journal: AJNR. American journal of neuroradiology

Published: March 14, 2024

New concept in neurovascular navigation: technical description and preclinical experience with the Bendit 17 and Bendit 21 microcatheters in a rabbit aneurysm model.

New concept in neurovascular navigation: technical description and preclinical experience with the Bendit 17 and Bendit 21 microcatheters in a rabbit aneurysm model.

Journal: Journal of neurointerventional surgery

Published: January 13, 2022

Evaluation of a novel flow diverter, the DiVeRt system, in an animal model.

Evaluation of a novel flow diverter, the DiVeRt system, in an animal model.

Journal: Journal of neurointerventional surgery

Published: February 15, 2021

Overcoming negative predictions of microRNA expressions to gemcitabine response with FOLFIRINOX in advanced pancreatic cancer patients.

Overcoming negative predictions of microRNA expressions to gemcitabine response with FOLFIRINOX in advanced pancreatic cancer patients.

Journal: Future science OA

Published: January 13, 2021

Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial.

Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial.

Journal: Journal of clinical medicine

Published: April 26, 2020

Expression of the microRNA-200 Family, microRNA-205, and Markers of Epithelial-Mesenchymal Transition as Predictors for Endoscopic Submucosal Dissection over Esophagectomy in Esophageal Adenocarcinoma: A Single-Center Experience.

Expression of the microRNA-200 Family, microRNA-205, and Markers of Epithelial-Mesenchymal Transition as Predictors for Endoscopic Submucosal Dissection over Esophagectomy in Esophageal Adenocarcinoma: A Single-Center Experience.

Journal: Cells

Published: December 12, 2019

Evaluation of circulating cell-free DNA as a molecular monitoring tool in patients with metastatic cancer.

Evaluation of circulating cell-free DNA as a molecular monitoring tool in patients with metastatic cancer.

Journal: Oncology letters

Published: January 28, 2019

Correction: The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab.

Correction: The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab.

Journal: The pharmacogenomics journal

Published: January 20, 2019

BIRC3 Expression Predicts CLL Progression and Defines Treatment Sensitivity via Enhanced NF-κB Nuclear Translocation.

BIRC3 Expression Predicts CLL Progression and Defines Treatment Sensitivity via Enhanced NF-κB Nuclear Translocation.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: May 18, 2018

DNA Methylation Signatures Predicting Bevacizumab Efficacy in Metastatic Breast Cancer.

DNA Methylation Signatures Predicting Bevacizumab Efficacy in Metastatic Breast Cancer.

Journal: Theranostics

Published: October 29, 2017

Clonal evolution and heterogeneity in metastatic head and neck cancer-An analysis of the Austrian Study Group of Medical Tumour Therapy study group.

Clonal evolution and heterogeneity in metastatic head and neck cancer-An analysis of the Austrian Study Group of Medical Tumour Therapy study group.

Journal: European journal of cancer (Oxford, England : 1990)

Published: August 21, 2017

Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).

Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).

Journal: BMC cancer

Published: April 15, 2017

Showing 1-12 of 27

Last Updated: 09/26/2026